XT
AVIR icon

XTX Topco’s Atea Pharmaceuticals AVIR Stock Holding History

XTX Topco’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,141
Closed -$124K – 4145
2026
Q1 		$124K Buy
23,141
+12,702
+122% +$58.3K ﹤0.01% 3027
2025
Q4 		$37.3K Sell
10,439
-11,836
-53% -$37.6K ﹤0.01% 2903
2025
Q3 		$64.6K Sell
22,275
-64,849
-74% -$221K ﹤0.01% 2115
2025
Q2 		$314K Buy
+87,124
New +$260K 0.01% 1398
2023
Q2 		– Sell
-32,630
Closed -$109K – 1410
2023
Q1 		$109K Buy
+32,630
New +$132K 0.02% 1081

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's AVIR Position: Q2 2026 in Review

XTX Topco sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 23,141 shares — an estimated $124K sold.

XTX Topco first reported a position in AVIR in Q1 2023 and held it in 5 quarters. The position peaked at $314K in Q2 2025. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • XTX Topco reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 23,141 Atea Pharmaceuticals shares in Q2 2026, an estimated $124K.
  • XTX Topco first reported a position in Atea Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • XTX Topco's Atea Pharmaceuticals position peaked at $314K in Q2 2025.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.